Skip to main content

Table 3 Baseline demographics and patients’ clinical characteristics of n = 79 women with breast cancer

From: Cancer treatment regimens and their impact on the patient-reported outcome measures health-related quality of life and perceived cognitive function

Variable Group SC Group SCR Group SR Group S
N. (%) 22 (100.0) 17 (100.0) 27 (100.0) 13 (100.0)
Age [years] 51.9 ± 11.6 54.4 ± 8.5 56.7 ± 9.0 55.3 ± 7.3
p 0.30 0.21 0.06 0.28
Age, 30–35 years n (%) 2 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
Age, 35–40 years n (%) 2 (9.1) 0 (0.0) 3 (11.1) 0 (0.0)
Age, 41–49 years n (%) 5 (22.7) 6 (45.5) 2 (7.4) 3 (23.1)
Age, 50–59 years n (%) 6 (27.3) 4 (23.5) 9 (33.3) 6 (46.2)
Age, 60–69 years n (%) 7 (31.8) 7 (41.2) 13 (48.2) 4 (30.8)
Height [m] 1.65 ± 0.08 1.65 ± 0.08 1.61 ± 0.06 1.63 ± 0.08
p 0.43 0.77 0.56 0.24
Weight [kg] 72.1 ± 14.2 82.7 ± 20.2 68.6 ± 12.4 72.6 ± 12.5
p 0.29 0.11 0.66 0.55
BMI [kg m−2] 26.4 ± 5.0 30.5 ± 6.8 26.4 ± 4.8 27.4 ± 4.3
p 0.08 0.08 0.48 0.17
UICC n (%) IA: 5 (22.7)
IIA:10 (45.5) IIIA: 1 (4.6)
IIB: 6 (27.3)
IA: 7 (41.2)
IIA:7 (41.2)
IB: 2 (11.8)
IIB: 1 (5.9)
IA: 25 (92.6)
IIA: 2 (7.4)
IB: 0 (0.0)
IIB: 0 (0.0)
IA: 5 (38.5)
IIA: 8 (61.5)
IB: 0 (0.0)
IIB: 0 (0.0)
TT (month) 7.7 ± 1.3 10.4 ± 1.6 5.3 ± 1.5 2.5 ± 1.6
Her2/neu status,
n (%)
Pos. 1 (4.5)
Neg. 21 (94.5)
Pos. 2 (11.8)
Neg. 15 (88.2)
Pos. 0 (0.0)
Neg. 27 (100.0)
Pos. 13 (100.0)
Neg. 0 (0.0)
ER status,
n (%)
Pos. 13 (59.1)
Neg. 9 (40.9)
Pos. 14 (82.4)
Neg. 3 (17.7)
Pos. 27 (100.0)
Neg. 0 (0.0)
Pos. 13 (100.0)
Neg. 0 (0.0)
MC, n (%) 1 (4.6) 1 (5.9) 0 (0.0) 0 (0.0)
IDC, n (%) 18 (81.8) 16 (94.1) 24 (88.9) 7 (53.9)
IDC-L, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (7.7)
ILC, n (%) 3 (13.6) 0 (0.0) 2 (7.4) 5 (38.5)
ICC, n (%) 0 (0.0) 0 (0.0) 1 (3.7) 0 (0.0)
SNB, n (%) 21 (95.5) 15 (88.2) 27 (100.0) 13 (100.0)
ALND, n (%) 5 (22.7) 3 (17.7) 0 (0.0) 0 (0.0)
BCS, n (%) 8 (36.4) 16 (94.1) 27 (100.0) 0 (0.0)
MRM, n (%) 2 (9.1) 1 (5.9) 0 (0.0) 2 (15.4)
SCM, n (%) 9 (40.9) 0 (0.0) 0 (0.0) 10 (76.9)
BCS + SCM, n (%) 3 (13.6) 0 (0.0) 0 (0.0) 1 (7.7)
TMX, n (%) 1 (4.5) 4 (23.5) 6 (22.2) 1 (7.7)
ALs, n (%) 13 (59.1) 9 (52.9) 20 (74.1) 11 (84.6)
Neoadjuvant C, n (%) 10 (45.5) 9 (52.9) 0 (0.0) 0 (0.0)
Adjuvant C, n (%) 13 (59.1) 8 (47.1) 0 (0.0) 0 (0.0)
Anth-bCTx, n (%) 12 (54.6) 9 (52.9) 0 (0.0) 0 (0.0)
TaxAnth-C, n (%) 10 (45.5) 8 (47.1) 0 (0.0) 0 (0.0)
R, n (%) 0 (0.0) 17 (100.0) 27 (100.0) 0 (0.0)
  1. Means ± standard deviation (SD); n = number of patients (%); normally distribution (Shapiro–Wilk test) p > 0.05; SCR, Surgery + Chemotherapy + Radiotherapy; SC; SR; S; ALND, Axillary lymph node dissection; ALs, Aromatase inhibitors; Anth-bC, Anthracycline-Based Chemotherapy; BCS, Breast-conserving surgery; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; ICC, invasive cribriform carcinoma; IDC, Invasive ductal carcinoma; IDC-L, invasive ductal carcinoma with lobular features; ILC, invasive lobular carcinoma; MC, Mucinous breast carcinoma; MRM, Modified Radical Mastectomy; R, Radiotherapy; SCM, Subcutaneous mastectomy; SNB, Sentinel node biopsy; TMX, Tamoxifen; TaxAnth-C, Anthracycline-Taxane-Based Chemotherapy; TT, Time of Treatment; UICC, Union for International Cancer Control